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ABSTRACT
Introduction: Mid-regional proadrenomedullin (MR-proADM), a novel biomarker, has recently gained 
interest particularly with regards to its potential in assisting clinicians’ decision making in patients with 
suspicion of infection in the emergency department (ED). A group of international experts, with 
research and experience in MR-proADM applications, produced this review based on their own 
experience and the currently available literature.
Areas covered: The review provides evidence related to MR-proADM as a triaging tool in avoiding 
unnecessary admissions to hospital and/or inadequate discharge, and identifying patients most at risk 
of deterioration. It also covers the use of MR-proADM in the context of COVID-19. Moreover, the authors 
provide a proposal on how to incorporate MR-proADM into patients’ clinical pathways in an ED setting.
Expert opinion: The data we have so far on the application of MR-proADM in the ED is promising. 
Incorporating it into clinical scoring systems may aid the clinician’s decision making and recognizing 
the ‘ill looking well’ and the ‘well looking ill’ sooner. However there are still many gaps in our knowl-
edge especially during the ongoing COVID-19 waves. There is also a need for cost-effectiveness analysis 
studies especially in the era of increasing cost pressures on health systems globally.
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1. Introduction
Adrenomedullin (ADM), a 52 amino acid peptide, is a member 
of the calcitonin peptide family [1] and is widely expressed in 
many tissues and organs. In healthy subjects, ADM circulates 
at low picomolar concentrations, but during pathological 
events, plasma concentrations are significantly up-regulated. 
Plasma concentration changes are proportional to disease 
severity [2].The increased stability of its precursor molecule, 
mid-regional proadrenomedullin (MR-proADM), allows a reli-
able measurement as a surrogate biomarker for the unstable 
ADM in a 1:1 ratio [3]. The assays can be performed on routine 
blood samples, and generally it takes around 30 minutes to 
get a result from the receipt of the sample in diagnostic 
laboratories.
Complications leading up to initial organ dysfunction in 
sepsis include factors such as impaired microcirculation, 
enhanced microvascular permeability, decreased numbers of 
perfused capillaries, endothelial cell apoptosis, and abnormal 
systemic blood flow to organ systems. During the pathophy-
siology and progression of sepsis, ADM levels are increased, 
leading to a reduction in vascular resistance and a significantly 
increased microvascular blood flow in many organs and sys-
tems such as the liver, small intestine, kidneys, and spleen [4]. 
The production of ADM has been shown to have beneficial 
properties in sepsis. These include having protection against 
endothelial permeability and consequent organ damage, pro-
tective effects in organs in response to bacterial induced 
shock, the ability to stabilize the microcirculation in inflamma-
tion, and the ability to restore endothelial stability in infected 
organs due to prevention of undesired inflammatory decom-
partmentalisation [5]. The body can facilitate localized cellular 
production and release of ADM in order to meet the specific 
perfusion requirements of individual organs which can be 
crucial in maintaining blood supply [6].
Whilst current benchmarks of sepsis, which include lactate 
and sequential organ failure (SOFA) scores, can accurately 
assess the degree of tissue hypoxia and organ dysfunction at 
any given time point, animal studies have shown that elevated 
MR-proADM levels can accurately reflect the early microvas-
cular changes that occur in the build up to subsequent organ 
damage and dysfunction [7], the majority of which are extre-
mely difficult to detect using standard clinical techniques, 
biomarkers or severity scores.
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Generally in the emergency department (ED), clinical scores 
and investigations are used to assist clinicians in their decision 
making. Although these can be helpful, they can also be 
misleading since patient factors such as age, comorbidities, 
and prior health status can play an important role in disease 
progression, outcome and mortality [8]. It is therefore also 
important to consider additional tools, such as blood biomar-
kers, that can better predict disease progression and mortality, 
that can be incorporated into clinical scoring systems, and 
other markers that can accurately differentiate the ‘ill looking 
well’ from the ‘well looking ill’. With this in mind, there are 
three main potential benefits of using MR-proADM in a con-
tinuously busy ED, which include; A) triaging patient care at 
the outset, B) avoiding unnecessary admissions to hospital or 
inadequate discharges, and C) identifying patients most at risk 
of deterioration or poor outcome for early escalation of their 
management including antibiotic treatment or admission to 
higher level care [9–11].
During the 2020 COVID-19 pandemic, the pressure on hos-
pital EDs, Intensive Care Units (ICU), and healthcare systems 
became more apparent globally. Hence a biomarker that can 
assist in easing off that pressure would be extremely valuable 
in clinical settings.
Accordingly, a group of international experts with research 
and experience in the applying MR-proADM to their clinical 
practice produced this review and aimed to:
(1) Review literature on Mid-regional pro-adrenomedullin 
(MR-proADM) in the emergency department (ED) and 
impact on clinical decision making in the emergency 
department
(2) Present current evidence and personal opinion from 
experts, including those related to COVID-19
(3) Agree to an algorithm or proposal on how to incorpo-
rate MR-proADM into patient clinical pathways and 
how to measure impacts of MR-proAM in EDs
(4) Propose conclusions and highlighting areas of future 
research and direction
2. Methodology
A multidisciplinary group of clinical experts from three 
countries met virtually during July 2020 to discuss topics 
related to MR-proADM applications in the ED, where key 
topics were agreed and selected for review.
A PubMed literature search was performed from inception 
to 15 July 2020, using the following search criteria [(proadre-
nomedullin OR proADM OR MR-proADM) AND (Emergency 
Department OR Emergency Room OR ED OR ER)) AND 
(infection)].
Each subtopic was assigned to at least two of the coauthors 
to draft the original articles related to each subtopic. 
Additionally, following the initial review, the number of papers 
have been published relating to MR-proADM in COVID-19 
patients, these have been included as well as authors own 
anecdotal experience where applicable to the final discussion.
These were forwarded to the lead author for critical review 
and an initial manuscript was compiled. All the authors had 
the chance to review and agree to the final submitted version 
of the article.
3. Results
The literature search yielded 34 papers, including three papers 
in Spanish, six reviews and meta-analyses which were all 
included in the review. The following themes were identified 
within these papers and were agreed by the authors who 
formed the main points of the discussion for the review:
(1) Current evidence related to MR-proADM as a triaging 
tool in cases with suspicion of infection (assisting in 
admission or avoid admission decisions) or as a disease 
progression tool including ICU admission and mortality 
in the ED
(2) MR-proADM as an antibiotic stewardship tool in the ED
(3) MR-proADM in the context of COVID-19 in ED: does it 
help to identify those at risk of disease progression
3.4Incorporating  MR-proADM into patient clinical pathways or 
algorithms
3.1. Current evidence related to MR-proADM as a tool in 
cases with suspicion of infection in the ED as A) a 
triaging tool assisting in admission or avoid admission 
decisions or B) as a disease progression tool including 
ICU admission and C) as prognostic tool and predictor of 
mortality
Emergency departments are increasingly under immense pres-
sure; with huge throughput causing prolonged waiting times 
for the patients. A safe and rapid triaging of patients with low 
risk of deterioration, that can be treated as outpatients is 
essential to improve the workflow within the ED without 
reducing patient safety and comfort, and alleviating any unne-
cessary financial burden from the healthcare provider. 
Additionally, a tool that can aid ED clinicians to early identify 
those at risk of disease progression could be immensely 
Article highlights
● Mid-regional proadrenomedullin (MR-proADM) is a novel biomarker 
Animal studies have shown that elevated MR-proADM levels can 
accurately reflect the early microvascular changes that occur in the 
build-up to subsequent organ damage and dysfunction during sepsis.
● Studies have shown the MR-proAD can be incorporated into clinical 
scoring systems, and other markers to accurately differentiate the ‘ill 
looking well’ from the ‘well looking ill’.
● It may assist clinicians decision making with regards to; A) triaging 
patient care at the outset, B) avoiding unnecessary admissions to 
hospital or inadequate discharges, and C) identifying patients most at 
risk of deterioration or poor outcome for early escalation of their 
management including antibiotic treatment or admission to higher 
level care.
● Limited data available for patients with COVID-19 and findings of 
these studies are promising however more studies are required to 
maximize our knowledge with regards to the full potential of MR- 
proADM in these patients.














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































EXPERT REVIEW OF MOLECULAR DIAGNOSTICS 3
valuable in planning escalations of level of care soon after 
patients’ presentation. Findings from the review are presented 
in (Table 1) [1,11–26].
Incorporating MR-proADM into clinical scoring as a guide 
to avoid admission and a triaging tool in the ED could safely 
increase the number of outpatients compared to standard 
practice; overcome over-crowded situations in the ED and 
redirect the ED resources to the severely ill patients. 
Additionally, the prognostic value of MR-proADM as marker 
of organ dysfunction is in agreement with clinical scores 
and early sepsis identification is critical to begin appropriate 
management and improve the clinical outcomes 
[12,19,20,22,27,28] More studies and prospective pragmatic 
trials are required to confirm these original experiences and 
data.
3.2. MR-proADM as an antibiotic stewardship tool inED
The early administration of antibiotics in patients presenting 
to ED with a suspected infection is a challenge for clinicians, 
who must balance the necessary early administration of anti-
biotics in severe cases against the over prescription and mis-
use of antibiotics that derive increasing antibiotic resistance 
and can have detrimental effects on the microbiota.
Biomarkers, e.g., MRproADM, PCT, and C-reactive protein 
(CRP), can aid clinicians in their antibiotic decision-making. A 
prospective study consecutively enrolled patients presenting 
with a suspected infection to the EDs of three large tertiary 
level university hospitals in Spain [22], found that patients 
with a low National Early Warning Score (NEWS) but high 
pro-ADM had worse outcomes if they were not treated with 
antibiotics. This included higher rates of ICU admission (27.3% 
vs 4.8%, p < 0.001) and infection-related hospital readmission 
(54.5% vs 14.3%, p < 0.001). Therefore, an early administration 
of antibiotics must be considered in patients with suspected 
infection especially with high MR-proADM concentrations.
A recent study [9] highlighted a greater association with 
the requirement for antibiotic administration using NEWS and 
MR-proADM, as opposed to more commonly used parameters 
such as CRP and PCT. The rapid kinetics of MR-proADM, which 
is released significantly earlier than many other cytokines in 
response to microbial infection, could be useful to identify 
high-risk patients in which early antibiotics are genuinely 
indicated. The results suggest that delayed antibiotic admin-
istration in patients with low MR-proADM concentrations 
(<1.27 nmol/L) may result in fewer adverse effects, potentially 
allowing for a more detailed clinical assessment and investiga-
tions prior to any subsequent antimicrobial initiation without 
negative impact on patients [9]. Hence MR-proADM could 
represent an interesting antibiotic stewardship tool, however 
again more studies are required to confirm this hypothesis.
3.3. MR-proADM and COVID-19 cases in ED does it help 
to identify those at risk of disease progression?
The new Coronavirus disease 2019 (COVID-19), a disease 
caused by the severe acute respiratory syndrome 
Coronavirus-2 (SARS-CoV-2) infection - continues to represent 
a major threat to global health [29].
COVID-19 is a systemic disease characterized by wide-
spread endothelial damage with multiple organ dysfunction 
syndrome, when infection evolves causing severe clinical con-
ditions, pneumonia and death [29]. Recently, to investigate the 
pathophysiological bases of organ failure development during 
COVID-19 disease, the involvement of endothelial cells at the 
interface between blood and parenchymal cells was evaluated 
[30]. COVID-19 related damage could resemble alterations 
observed during sepsis, and also in this case alteration of 
MR-proADM release could be suggested during SARS-CoV2 
infection [30–32].
In COVID-19 infections, patients’ clinical condition can wor-
sen abruptly and unpredictably with many patients seemingly 
improving before deteriorating. As a result, the workload in 
ED, general wards, and ICUs has dramatically increased almost 
everywhere, creating a pressing need to optimize resources 
through risk stratification for critically ill COVID-19 patients. 
Interestingly, Li H. et al. [33] recently hypothesized that in 
critical patients with COVID-19-related pneumonia, the integ-
rity of the epithelial-endothelial barrier was severely inter-
rupted, describing a particular syndrome denominated ‘viral 
sepsis’. MR-proADM may prove to be effective in risk stratifica-
tion for patients affected by viral sepsis.
Recent studies have highlighted the value of PCT as a 
useful tool for antibiotic stewardship in COVID-19 patients in 
the intensive care unit. Patients in the first week of admission 
with a low PCT had 2 days less exposure to antibiotics with 
comparable outcomes [34]. A study tested the effectiveness of 
MR-proADM in comparison to C-reactive protein (CRP), procal-
citonin (PCT), D-dimer, and lactate dehydrogenase (LDH) in 
predicting disease progression and mortality in 57 COVID-19 
ICU-patients. MR-proADM, clinical and other routine laboratory 
tests were measured within 48 hours from ICU admission, on 
day 3, 7 and 14. Survival curves difference with MR-proADM 
cutoff set to 1.8 nmol/L were tested using log-rank test. ICU 
and overall mortality were 54.4%. MR-proADM was higher in 
dying patients (2.65 + 2.33 vs 1.18 + 0.47, p = 0.0001) and a 
higher mortality characterized patients with MR-proADM 
exceeding 1.8 nmol/L (p = 0.0157) [35].
An observational study investigated the association of MR- 
proADM levels with in-hospital mortality. The study included 
89 critically ill COVID-19 patients, 19% (n = 17) died while in 
the hospital. Median admission MR-proADM levels were 
increased almost 1.5-fold in non-survivors compared to survi-
vors (1.3 (IQR 1.1 to 2.3) vs. 0.8 (IQR 0.7 to 1.1) difference, P 
value) and showed good discrimination (AUC 0.78). An 
increase of 1 nmol/L of admission MR-proADM was indepen-
dently associated with a more than fivefold increase in in- 
hospital mortality (adjusted odds ratio (OR) of 5.5, 95%CI 1.4 
to 21.4, p = 0.015). An admission MR-proADM threshold of 
0.93 nmol/L showed the best prognostic accuracy for in-hos-
pital mortality with a sensitivity of 93%, a specificity of 60%, 
and a negative predictive value of 97%. Kinetics of follow-up 
MR-proADM provided further prognostic information for in- 
hospital treatment. The study concluded that increased levels 
of MR-proADM on admission and during hospital stay were 
independently associated with in-hospital mortality and may 
allow a better risk stratification, and particularly rule-out of 
fatal outcome in COVID-19 patients [36].
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In another prospective observational study among 99 adult 
patients hospitalized with confirmed COVID-19. Twenty-five 
(25.3%) cases progressed to severe disease (defined as a com-
posite of admission to Intensive Care Unit and/or need for 
mechanical ventilation and/or 28-day mortality) and the 28- 
day mortality rate was of 14.1%. MR-proADM showed the 
highest AUC to predict 28-day mortality (0.905; [CI] 95%: 
0.829–0.955; P < 0.001) and progression to severe disease 
(0.829; [CI] 95%: 0.740–0.897; p < 0.001), respectively. MR- 
proADM plasma levels above optimal cutoff (1.01 nmol/L) 
showed the strongest independent association with 28-day 
mortality risk (hazard ratio [HR]: 10.470, 95% CI: 2.066– 
53.049; p < 0.005) and with progression to severe disease 
(HR: 6.803, 95% CI: 1.458–31.750; p = 0.015) [37].
Furthermore, results from a pragmatic retrospective 
including 111 patients, admitted to Udine University 
Hospital due SARS-CoV-2 pneumonia, showed an associa-
tion between MR-proADM levels and the severity of 
COVID-19: high MR-proADM levels were significantly asso-
ciated with combined events of death or orotracheal intu-
bation (OR 4.284 [95%CI 1.893–11.413]). AUROC analysis 
showed a good discriminative performance of MR-proADM 
(AUROC: 0.849 [95% Cl 0.771–0.730]; p < 0.0001). 
Additionally the identified that the optimal value of MR- 
proADM, associated with negative outcome, was 
0.895 nmol/l (sensitivity 0.857 [95% Cl 0.728–0.987]; specifi-
city of 0.687 [95% Cl 0.587–0.787]) [38]. This cutoff value is 
almost identical to the value previously found to be a good 
level to safely discharge patients with other infections from 
ED [1].
Extrapolating results from bacterial infection and sepsis to 
COVID-19 is a major limitation, while results on these small- 
scale COVID-19 studies are promising, larger and randomized 
trials are urgently required to assess MR-proADM use in the 
diagnosis and prognosis of COVID-19 patients, particularly 
when the impact of steroids and tocilizumab on the outcome 
of COVID-19 and impact on MR-proADM in COVID-19 patients.
3.4. Incorporating MR-proADM to patients clinical 
pathways or algorithms
Despite increasing numbers of publications and studies, the 
uptake of MR-proADM in clinical practice has been generally 
low. This is likely to be due to many reasons including lack 
of guidance on how to best integrate MR-proADM test 
results into the clinical management of patients attending 
EDs, and lack of national or international bodies to support 
its use, which is again due to lack of clinical trials, sufficient 
clinical data, large numbers of studies, and cost effective-
ness analysis.
The main point from a recent med-tech innovation brief-
ing by the National Institute for Health and Care Excellence 
(NICE) [10] suggested that the available studies, at the time 
of the review, show that MR-proADM can improve accuracy 
of infection diagnosis and can predict the infection’s sever-
ity. However, there is a lack of prospective studies showing 
how MR-proADM results influence clinical decisions. 
Following this review a randomized-controlled 2-arms 
study demonstrated 20% more patients could be managed 
in the outpatient setting safely [22].
While we agree with NICE’s finding, we would like to 
propose the following algorithms which can be considered 
for future clinical evaluations and/or studies. The proforma 
allows for comparing data among studies, local reports, and 
real-life publications (Table 2). Again we must emphasize 
that no biomarker can replace clinician experience and this 
will always override any diagnostic results.
4. Discussion and further research
Misdiagnosis is one of the most common errors in the ED 
settings, and diagnosis of bacterial infection can be very chal-
lenging during the initial assessment of patients or in certain 
patient groups, e.g., in elderly patients where classical features 
of infection or sepsis could be absent. Indeed, the confusion 
between cardiovascular events and infections is the most 
common misdiagnosis in studies that evaluate discrepancies 
between clinical diagnosis and autopsy findings [39].
In patients with suspicion of infection, MR-proADM levels 
can provide clinicians with a more accurate reflection of 
abnormalities in the microcirculation before the patient devel-
ops any form of organ dysfunction or adverse clinical signs 
become apparent. Limited number of studies which are 
mostly observational have shown that MR-proADM could 
represent one of the most valuable tools in identifying 
infected patients at risk of disease progression and poor clin-
ical outcomes. High levels of MR-proADM despite low clinical 
scores in patients are associated with greater risk of disease 
progression, ICU admission, and mortality, as well as a higher 
readmission rates for EDs. However, published studies have 
concentrated on bacterial infection; viral infections have been 
poorly investigated even before COVID-19 with regards to the 
impact of MR-proADM on their management and outcome. 
Therefore, pragmatic clinical trials and studies are required to 
maximize our knowledge regarding the potential of MR- 
proADM and its clinical implications in making-decisions and 
impact on patients outcomes and health economics as well as 
studies and trials specifically with regards to COVID-19 −19 
pandemic as it looks like SARS-CoV-2 is going to stay with us 
for a protracted period.
5. Expert opinion
There are still big gaps in our knowledge with regards to novel 
biomarkers and their application in clinical practice. MR- 
proADM is one of these novel markers that recently gained 
much interest in clinicians and researchers particularly with 
regards to its ability to support or be incorporated into clinical 
scoring systems and aiding clinicians to recognize deteriorat-
ing patients who appear to be well looking and vice versa as 
well as in predating who requires higher levels of care and 
outcomes.
The data summarized in this review represent mostly what 
is available and from experts that have used MR-proADM in 
their practice. Although what we know now is very promising, 
we are still in need of larger studies and evaluations to max-
imize our knowledge and recognize the full potential of MR- 
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proADM. Although MR-proADM can be measured easily 
through a blood test and results could be available within 
30 minutes from receiving a sample in a diagnostic laboratory, 
the marker itself hasn’t universally taken off, yet, due to a 
number of reasons. These could be, lack of large randomized 
multicentre studies, availability of suitable wide range plat-
forms in diagnostic laboratories; lack of diagnostic point of 
care test that could be used by the bed-site, outside research; 
lack of wide experience by clinicians; lack of cost effectiveness 
analysis studies and lack of international consensus or gui-
dance on how to use and what cut offs should be adopted, 
e.g., in emergency settings. All these are questions requiring 
answers and answers can be obtained through systematic, 
randomized studies and evaluations.
Additionally using MR-proADM, alone and in combination 
with other biomarkers, has not yet fully appreciated in the 
emergency departments during COVID-19 waves and how it 
may assist in triaging patients, admission avoidance, and prog-
nostication. There are limited real-life reports and retrospec-
tive studies highlighting the potential that MR-proADM could 
have, but these findings need confirmation in larger studies, 
especially in the era of increasing demand for hospital beds 
and cost pressures on health systems globally.
There are now, and in many corners of the world, point of 
care diagnostics that are being used in various settings includ-
ing home settings and virtual wards. Examples of these 
include point of care COVID-19 tests. We think. In the future, 
affordable point of care measurements of MR-proADM from a 
single blood drop with other biomarkers will be immensely 
helpful in settings like home settings, outpatients and virtual 
wards, emergency rooms, general practice, and even inside 
ambulances.
Availability of this marker with others as well as a diagnos-
tic test for, e.g., COVID-19 will help not only clinicians and 
health care providers, but also individuals to make more 
informed decisions whether to seek further medical advice 
or even attend a hospital for further evaluation. Or these 
diagnostic could be linked to a mobile phone application, 
linked to an artificial intelligence system, the net outcome of 
it will be an instruction to the user of what the best action is.
Additionally for clinicians in the above settings, incorporat-
ing MR-proADM levels into clinical scoring systems and other 
biomarkers could make their decision around patients triaging 
more individualized, e.g., safe discharge or avoid admissions 
or rapid escalation of treatment to high dependency or inten-
sive care which overall will be beneficial to both healthcare 
systems and patient outcomes. Furthermore a meta-analysis of 
the existing studies on the proposed cutoffs of risk prediction 
with MR-proADM for bacterial sepsis based on publications 
before COVID-19 and comparing it to findings from COVID-19 
studies is required.
Until then we encourage collaboration between healthcare 
providers, industries, and funding agencies to assist in studies 
that provide answers to the gaps highlighted above.
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Table 2. An action table that may be considered for future evaluations and/or clinical studies following MR-rroADM results (could be modified according to local 
needs).
Pro‐ADM levels  nmol / L  and potential ACTIONS◊
<0.87 >0.87‐1.5 >= 1.5 
Patients clinically well (Defined by setting 
specific scores, e.g. SOFA <2, qSOFA<2, 
NEWS2 < 5) * 
Discharge with safety net** Ward based admission 
Repeat MR‐proADM in 12‐24 hours to 
assess progress and potential discharge 
depending on clinical scoring and the trend 
of MR‐proADM levels 
Admit to acute admissions  
Closely monitor clinical scoring and picture 
Secondary examinations and review 
Monitor daily MR‐proADM to assess progress 
and plan escalation or de‐escalation of 
therapy based on combinations of these 
findings   
Patients is clinically unwell OR clinican 
concern (Defined by setting specific 
scores, e.g. SOFA  ≥2, qSOFA ≥ 2, NEWS 
≥5)  
Potentially discharge  patients 
with safety net**   
Admit to acute admissions, consider ICU/ HDU 
outreach depending on senior review 
Closely monitor clinical scoring and picture 
Secondary examinations and review 
Monitor daily MR‐proADM to assess progress 
and plan escalation or de‐escalation of 
therapy based on combinations of these 
findings   
* Please consider other local scoring systems; clinician’s decision could override the test result at any time based on their clinical assessment 
**advice patient to come back if noticed clinical deterioration 
◊ The following are some examples on what impacts need to be accounted or measured to further assess the impact of MR-proADM: 
1) The number of admissions and discharges that were influenced by measuring MR-proADM levels, vs total number of admissions and discharges in the EDs 
2) The number of admissions to HDU and ICU that were influenced by measuring MR-proADM levels, vs total number of admissions and discharges to these areas 
3) Impact of the above decisions on subsequent mortality within 30 days of that decision 
4) Impact of those decisions on earlier discharges and subsequent readmission rates (within 30 days) 
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